Abstract: A composition for in situ formation and/or expansion of a polymer-based hemostatic agent to control bleeding includes a suitable amount of a polymer or polymer-forming component, hydrogen peroxide or chemical(s) capable of forming hydrogen peroxide, or a combination of both, and a decomposing agent for hydrogen peroxide. The decomposing agent includes an endogenously or exogenously supplied catalyst (other than catalase), or both, and/or the polymer or polymer-forming component.

Abstract: The present disclosure provides an immediate release, abuse deterrent pharmaceutical solid dosage form comprising at least one functional score. In particular, the immediate release, abuse deterrent solid dosage form comprises at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system.

Abstract: A composition for in situ formation of an artificial blockage to control bleeding includes a suitable amount of a polymer-forming component, a suitable amount of a crosslinking agent, hydrogen peroxide, and a decomposing agent for hydrogen peroxide. The decomposing agent includes exogenous or endogenous catalase, or both.

Abstract: Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described.

Abstract: A gastroretentive, extended release composition which floats and swells at acidic pH prevalent in the stomach. The composition includes a pH dependent graft copolymer, a gellable polymer, a therapeutic agent, a gas generating system and pharmaceutically acceptable ingredients. The disclosed composition is useful to deliver the therapeutic agent within the stomach for an extended period of time.

Abstract: This invention relates to an orally administrable, gastroretentive pharmaceutical dosage form which contains at least one pharmaceutically active ingredient and at least one polymeric adjuvant. The adjuvant serves to retain the dosage form in a selected region of the gastrointestinal tract for sufficient time for the pharmaceutically active ingredient to be released and absorbed. Ideally the dosage form will contain two or more pharmaceutically active ingredients which are delivered to different regions of the gastrointestinal tract.

Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of additional pH adjusting substance in combination with the effervescent for promoting the absorption of drugs is also disclosed.

Abstract: Disclosed is pesticidal particulate composition of matter, the particles comprising active substances, which react upon contact inside a pest body, the reaction generating a gaseous product and/or heat which destroy the pest. Pesticidal preparations, methods and kits are also disclosed.

Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.

Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.

Abstract: In one aspect, the present invention is directed to formulations comprising at least one pressure generating vehicle along with at least one skincare active agent in a container such that the pressure generating vehicle would eject the formulation as foam, whipped cream or a similar form upon application of external pressure on the container.

Abstract: A mucosal or cutaneous medicinal or hygiene system, comprising (a) a gas-driven foam dispenser; and (b) a fluid composition comprising (i) as the only foaming agent one or more polysaccharides, gelatins, synthetic polymers selected from the group consisting of ethylene oxide homo- and copolymers having a weight average molecular weight of at least 10,000, and homo and copolymers comprising in polymerized form acrylic acid, an acrylic acid salt, acrylamide, vinylalcohol, vinylacetate, vinylpyrrolidone or vinylpyridine, or a combination thereof; (ii) a liquid diluent, and (iii) an active ingredient for mucosal or cutaneous medicinal treatment or hygiene.

Abstract: The invention features pharmaceutically acceptable salts of cefdinir, including primary, secondary, and tertiary amine salts of cefdinir, and preparation methods, and pharmaceutical compositions including cefdinir. The invention also features water dispersible pharmaceutical dosage forms including cefdinir as active agent and methods for preparing the dosages. The invention also features tablet forms of cefixime characterized in that the tablets are in effervescent form. The invention also features the process for preparing effervescent tablet forms with cefdinir as active agents and pharmaceutical formulations obtained by the process.

Abstract: The invention relates to an effervescent tablet for preparing a mouth rinsing solution, wherein the effervescent tablet exhibits a high release rate of budesonide. A high availability of the active ingredient during use as a mouth rinsing solution on the inflamed mucosa of the upper digestive tract is thereby achieved. The advantage of the formulation according to the invention lies in the bioavailability comparable to oral forms of administration, which allows the formulation to be used safely over an extended period of time.

Abstract: The treatment of acute pain with a sufficient dosage by intranasal administration of fentanyl results in a time to onset of action comparable to intravenous administration and a significantly faster onset of action than nasal titration of fentanyl. The nasal administration of a sufficient amount of fentanyl to obtain pain relief has lower maximum plasma concentrations comparable to intravenous administration and results in lower rates of adverse events like respiratory depression, nausea and vomiting. Compositions for use in the method are also disclosed.

Abstract: Antimicrobial mixtures comprising or consisting of: one or more branched or unbranched alkanediols having 6-12 carbon atoms, one, two or more compounds chosen from the group consisting of the tropolones of the formula (I) wherein the substituents R1, R2, R3, R4 and R5 independently of one another have the following meaning: H; linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; OH; OR6, wherein R6 is a linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; COOH; COOR7, wherein R7 is a linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; NO2; NH2; F, Cl, Br, I; are described.

Abstract: The present invention relates to water-soluble formulations comprising the active agent dexketoprofen and to a process for production of said formulations. The present invention also relates to pharmaceutical formulations comprising dexketoprofen which is used in symptomatic treatment of mild to moderate pains such as musculoskeletal pains, dysmenorrhoea, toothache, post-operative pains. The formulations are characterized in being in effervescent form.

Abstract: The subject of the invention is a veterinary product or a nutrition product intended in particular for the prevention and treatment of hypocalcaemia in ruminant animals. The product is in the form of a bolus comprising calcium carbonate and calcium formate. Advantageously, two of these boluses are concomitantly administered, one being a rapid-release effervescent bolus and the other being a slow-release bolus.

Abstract: An ozone delivery system, method, and apparatus are disclosed. Ozonated water can be used to disinfect and clean various surfaces, equipment, and animals in a dairy setting. Animals can be disinfected and protected from disease through the use of wash-pen and sprayer injections, and other footbath products. Ozone can be educted into a drop hose and a pre-dip line at periodic intervals and into a foot bath to provide refreshed ozonated water. The ozone delivery system and method sterilizes all equipment and floor surfaces without damaging diary equipment components. The system can incorporate computer-controlled options such as maintaining off gas levels, maintaining cleaning and disinfecting records, monitoring ozonated water levels, monitoring concentrations of ozone in said ozonated water, controlling entry and exit gates, controlling a drainage system, and monitoring and educting ozone in a foot bath and wash pen.

Abstract: A tumor-targeting gas-generating nanoparticle, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same relate to a tumor-targeting gas-generating nanoparticle including a polycarbonate core and a amphiphilic coat, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same. Since a tumor-targeting gas-generating nanoparticle according to the present disclosure is accumulated in the tumor tissue in large quantity and generates strong ultrasound wave signals, it can be usefully used as a contrast agent for ultrasonic imaging.

Abstract: Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described.

Abstract: A stable effervescent tablet, granule or powder composition free from excipients that may react with an effervescing organic acid component, comprising, an effective amount of a bisphosphonate bone resorption inhibitor, an effervescing organic acid component, an effervescing base component; wherein said composition is free of polyol binders and tableting lubricants; has a loss on drying of 0.25% (m/m) or less; has a complete disintegration time of no more than 180 seconds when placed in 3 to 8 fluid ounces of water at between 5-20° C.; and said bisphosphonate is incorporated as a micronized particle or by spray drying and is completely solubdised in water within 2 minutes without stirring.

Abstract: The present disclosure provides pharmaceutical compositions and processes for making solid dosage form pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. The pharmaceutical compositions provided herein comprise at least one pharmaceutically active ingredient, at least one low molecular weight water-soluble polymer, at least one polyglycol, at least one polysaccharide, at least one clay mineral, and, optionally, an effervescent system.

Abstract: The present disclosure provides pharmaceutical compositions and processes for making solid dosage form pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. The pharmaceutical compositions provided herein comprise at least one pharmaceutically active ingredient, at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system.

Abstract: Porous calcium phosphate implant compositions that approximate the chemical composition of natural bone mineral are provided. In addition to calcium phosphate, the compositions include an effervescent agent to promote the formation of interconnected pores and a cohesiveness agent to maintain the shape and hardness of the hardened composition. When introduced at an implant site, the calcium phosphate compositions are remodeled into bone. Methods for using the calcium phosphate compositions, e.g., to repair or replace bone, are also provided.

Abstract: An effervescent composition is provided comprising a dry, free-flowing powder comprising (a) microcapsules comprising a hollow, solid, water soluble outer shell comprising a starch, a sugar or mixtures thereof and an inner core comprising a liquid, water immiscible oil comprising at least one polyunsaturated fatty acid, at least one derivative of a polyunsaturated fatty acid or mixtures thereof, and (b) an effervescing agent.

Abstract: This invention relates to new methods of treating parasitic infections, such as trichomonas vaginalis infection and cecum amoeba infection, using L-enantiomer enriched ornidazole, in particular enantiomerically pure L-ornidazole, which provides benefits such as higher efficacy and lower toxicity to central nervous system over the existing racemic Ornidazole drug. New methods of synthesizing L- and D-enantiomers of Ornidazole in high purity and enantiomeric excess (ee), new formulations of the enantiomerically enriched L- or D-ornidazole, as well as their preparation processes and methods of use, are also disclosed.

Abstract: The present invention relates to the process for the preparation of the pharmaceutical formulations comprising a cephalosporin antibiotic and clavulanic acid or any pharmaceutically acceptable derivative thereof. The present invention also relates to processes for preparation of said formulations and their use in bacterial infections.

Abstract: The present invention relates to effervescent formulations comprising genistein with an average particle size (d50) in the range of 1 to 300 ?m as active agent. The present invention also relates to pharmaceutical formulations with high bioavailability comprising calcium, genistein and vitamin D in order to be used in prophylaxis and treatment of osteoporosis and related diseases.

Abstract: The invention relates to aboveground plant parts of Sideritis ssp. or extracts produced therefrom for use to boost cognitive performance.

Abstract: The present invention comprises an effervescent composition containing an antiseptically effective amount of phytochemicals, flavonoids, and/or antimicrobial agents comprising an effective amount of polyphenols derived from a plant selected from the group consisting of White tea, Green tea, Oolong tea, Black tea, camellia sinensis, thea sinensis, thea bohea, thea assamica, camellia thea, and combinations thereof. An effervescent powder, tablet, capsule film. Strip, or coating of effervescent powder for oral use is produced containing a pharmaceutically acceptable carbon dioxide source selected from the group consisting of a bicarbonate salt, a carbonate salt, and mixtures thereof; an organic acid and flavonoids and polyphenols derived from a plant selected from the group consisting of White tea, Green tea, Oolong tea, Black tea, camellia sinensis, thea sinensis, thea bohea, thea assamica, camellia thea, and combinations thereof. Desired profiles of catechins and the products of fermentation may be produced.

Abstract: The invention relates to oral dosage forms of pregabalin, preferably for the modified release, and to processes for producing it.

Abstract: Compositions which contain an active ingredient, a propellant containing a hydrofluoroalkane (HFA), a co-solvent, and a low-volatility component are useful for administering the active ingredient via an aerosol.

Abstract: The present invention provides devices and methods for treating wounds. The devices may include polymer particles capable of absorbing fluid such as blood. When devices of the invention are exposed to fluid, the fluid may enter the device and cause the polymer particles to swell. Devices of the invention may also apply pressure on wound cavities to stop or restrict the flow of fluid. In some embodiments, the devices may comprise components to facilitate absorption of fluid throughout the device, such as wicking elements and/or multiple compartments. One or more of the devices can be placed directly in the wound cavity, or in a containment structure and then into the wound cavity.

Abstract: The present invention relates to a process for preparing effervescent dosage forms comprising at least one antibiotic of cephalosporin group. The present invention also relates to effervescent formulations and preparations comprising antibiotics of second generation cephalosporin.

Abstract: The invention features pharmaceutically acceptable salts of cefdinir, including primary, secondary, and tertiary amine salts of cefdinir, and preparation methods, and pharmaceutical compositions including cefdinir. The invention also features water dispersible pharmaceutical dosage forms including cefdinir as active agent and methods for preparing the dosages. The invention also features tablet forms of cefixime characterized in that the tablets are in effervescent form. The invention also features the process for preparing effervescent tablet forms with cefdinir as active agents and pharmaceutical formulations obtained by the process.

Abstract: A gastroretentive, extended release composition which floats and swells at acidic pH prevalent in the stomach. The composition includes a pH dependent graft copolymer, a gellable polymer, a therapeutic agent, a gas generating system and pharmaceutically acceptable ingredients. The disclosed composition is useful to deliver the therapeutic agent within the stomach for an extended period of time.

Abstract: A cosmetic product includes at least: a first anhydrous cosmetic composition including at least colouring particles that are solid at room temperature and atmospheric pressure, the particles being formed from: at least one hydrophilic dyestuff in a content of greater than or equal to 60% by weight relative to their total weight, at least one effervescent system in a content of less than or equal to 20% by weight relative to their total weight, at least one hydrophilic binder, and at least one dispersant that is different from the hydrophilic binder; and a second composition comprising at least one aqueous phase.

Abstract: Porous calcium phosphate implant compositions that approximate the chemical composition of natural bone mineral are provided. In addition to calcium phosphate, the compositions include an effervescent agent to promote the formation of interconnected pores and a cohesiveness agent to maintain the shape and hardness of the hardened composition. When introduced at an implant site, the calcium phosphate compositions are remodeled into bone. Methods for using the calcium phosphate compositions, e.g., to repair or replace bone, are also provided.

Abstract: A method for antimicrobial treatment (e.g. antimicrobial treatment of food packaging and equipment) comprising applying to microbes a composition containing a diluting solvent (e.g., water), an antimicrobially-active solvent having a density different from the density of the diluting solvent, and an optional cosolvent, surfactant, or additional antimicrobial agent, wherein the amount of antimicrobially-active solvent or additional antimicrobial agent is sufficiently high and the amount of cosolvent or surfactant is sufficiently low so that the composition will provide greater than a 1-log order reduction in the population of bacteria or spores of Bacillus cereus within 10 seconds at 60° C. Preferred methods of the invention employ compositions containing an additional antimicrobial agent such as peroxyacetic acid. Compositions for use in the method can be prepared as concentrates, and used full strength or in diluted form.

Abstract: An innovative pharmaceutical form for controlled drug release relates to systems obtained by the assembly of individual release modules, of which the capacity to release the drug in time and in space depends on the way in which the modules have been assembled. The modular structure offers high reproducibility of manufacture and flexibility of release.

Abstract: An innovative pharmaceutical form for controlled drug release relates to systems obtained by the assembly of individual release modules, of which the capacity to release the drug in time and in space depends on the way in which the modules have been assembled. The modular structure offers high reproducibility of manufacture and flexibility of release.

Abstract: Non-pressurized shaving compositions are described that provide a warm/hot sensation during use as the result of an exothermic redox reaction. The compositions are post-foaming via nascent gas release in situ due to the generation of carbon dioxide. The carbon dioxide induced foam is maintained for several minutes after the compositions are dispensed, whereby the compositions are capable of providing both a warm sensation and sustained lather, a balance which heretofore has been a significant challenge.

Abstract: This invention provides a tablet that effervesces and significantly warms the water that it is dissolved in. The effervescence acts to break up the tablet allowing an exothermic material to rapidly dissolve releasing its heat of solution. The invention is unique in that no organic acid is required to form a conventional effervescent couple.

Abstract: A binary composition is provided comprising two liquids, which are separately maintained prior to forming an admixture during delivery to a hard surface, vessel, or drain. The admixture generates foam of sufficient stability and quantity to effect disinfection and biofilm removal. A first liquid preferably includes a quaternary ammonium compound, a peroxygen agent and, optionally, surfactants, thickening and chelating agents (colorants, corrosion inhibitors, stabilizers, perfume, etc). The second liquid preferably includes a hypohalite generating agent, a source of alkalinity, and optionally, a surfactant and thickening and chelating agents (colorants, corrosion inhibitors, stabilizers, perfume, etc.). Because the two liquids are initially separated, the hy-pohalit and peroxygen agent can be maintained in an environment that is favorable to their stability until the time of use. When the two liquids are mixed, the hypohalite and peroxygen react to liberate oxygen gas.

Abstract: The present invention relates to taste-masked oral formulations of influenza antivirals. The taste-masked pharmaceutical formulations for oral administration comprise one or more influenza antivirals, at least one taste-masking agent and at least one pharmaceutically acceptable excipient. Further, the taste-masked influenza antiviral formulations of the present invention are provided in the form of dispersible tablets, effervescent tablets, orally disintegrating tablets, chewable tablets, bite-dispersion tablets or the like, wherein the bitter taste of influenza antivirals is masked thereby providing palatable formulations.

Abstract: The treatment of acute pain with a sufficient dosage by intranasal administration of fentanyl results in a time to onset of action comparable to intravenous administration and a significantly faster onset of action than nasal titration of fentanyl. The nasal administration of a sufficient amount of fentanyl to obtain pain relief has lower maximum plasma concentrations comparable to intravenous administration and results in lower rates of adverse events like respiratory depression, nausea and vomiting. Compositions fur use in the method are also disclosed.

Abstract: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.

Abstract: The invention relates to a film-shaped form of administration for topically administering at least one agent and/or nutrient to a living being. Said form of administration comprises at least one agent-containing and/or nutrient-containing layer that is based on crosslinked hydrophilic polymers which are crosslinked with at least one polyacrylic acid derivative.

Abstract: A method of providing zinc to a subject in need of treatment includes administering to the subject an effective amount of a sustained-release zinc composition.